FDA
-
-
-
-
-
-
-
MediciNova Announces Closing of Underwritten Public Offering of Common Stock
-
-
-
-
-
-
-
MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
-
-
-
-
-
-
-
Medicinova (MNOV) Presents Additional Positive Top-Line Results from SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS
-
-
-
-
-
-
-
MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentat
-
-
-
-
-
323,881 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

